Fluvoxamine

Generic Name: Fluvoxamine

Brand Names: Luvox

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁F_₃N_₂O_₂

CAS Number: 54739-18-3

Unique Ingredient Identifier: O4L1XPO44W

Background: Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
...

Indication: Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) . Has also been used in the management of bulimia nervosa .

Associated Conditions: Bulimia Nervosa, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Paroxetine
Drug: Fluvoxamine
Drug: Itraconazole
Drug: ASN51

First Posted Date: 2024-01-30

Last Posted Date: 2024-12-18

Lead Sponsor: Asceneuron S.A.

Target Recruit Count: 50

Registration Number: NCT06232109

Locations: 🇳🇱
ICON Groningen Van Swietenlaan 6, Groningen, Netherlands

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

Phase 3

Completed

Conditions: Covid19

Interventions: Other: Placebo
Drug: Fluvoxamine

First Posted Date: 2023-06-08

Last Posted Date: 2024-11-15

Lead Sponsor: Susanna Naggie, MD

Target Recruit Count: 1208

Registration Number: NCT05894564

Locations: 🇺🇸
Morehouse School of Medicine, Atlanta, Georgia, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 99 locations

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

Phase 3

Completed

Conditions: Covid19

Interventions: Other: Placebo
Drug: Fluvoxamine

First Posted Date: 2023-06-06

Last Posted Date: 2023-09-26

Lead Sponsor: Susanna Naggie, MD

Target Recruit Count: 1331

Registration Number: NCT05890586

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Jadestone Clinical Research, LLC, Rockville, Maryland, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 87 locations

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Male Subjects

Interventions: Drug: Savolitinib
Drug: Fluvoxamine

First Posted Date: 2023-06-05

Last Posted Date: 2023-08-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT05888207

Locations: 🇺🇸
Research Site, Brooklyn, Maryland, United States

Fluvoxamine for Long COVID-19

Phase 2

Active, not recruiting

Conditions: Long COVID

Interventions: Drug: Fluvoxamine

First Posted Date: 2023-05-24

Last Posted Date: 2024-11-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 191

Registration Number: NCT05874037

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)
Antipsychotic Induced Weight Gain

Interventions: Drug: Miricorilant
Drug: Fluvoxamine

First Posted Date: 2023-02-03

Last Posted Date: 2023-03-22

Lead Sponsor: Corcept Therapeutics

Target Recruit Count: 26

Registration Number: NCT05712265

Locations: 🇺🇸
Site 01, Miami, Florida, United States

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Phase 2

Withdrawn

Conditions: Olfactory Disorder
Parosmia
COVID-19

Interventions: Drug: Placebo
Drug: Fluvoxamine

First Posted Date: 2022-01-31

Last Posted Date: 2022-03-11

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT05216614

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Caffeine
Drug: ABX464
Drug: Fluvoxamine

First Posted Date: 2021-11-16

Last Posted Date: 2022-01-05

Lead Sponsor: Abivax S.A.

Target Recruit Count: 59

Registration Number: NCT05121714

Locations: 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom

ACTIV-6: COVID-19 Study of Repurposed Medications

Phase 3

Completed

Conditions: Covid19

Interventions: Other: Placebo
Drug: Metformin
Drug: Ivermectin
Drug: Fluvoxamine
Drug: Fluticasone
Drug: Montelukast

First Posted Date: 2021-05-13

Last Posted Date: 2024-11-13

Lead Sponsor: Susanna Naggie, MD

Target Recruit Count: 10956

Registration Number: NCT04885530

Locations: 🇺🇸
Emory Healthcare, Atlanta, Georgia, United States
🇺🇸
Northwestern Univesity, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 106 locations

Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Fluvoxamine

First Posted Date: 2021-01-22

Last Posted Date: 2022-08-23

Lead Sponsor: SigmaDrugs Research Ltd.

Target Recruit Count: 66

Registration Number: NCT04718480

Locations: 🇭🇺
Dél-pesti Centrumkórház, Budapest, Hungary
🇭🇺
Debreceni Egyetem Kenézy Gyula Kórház Infektológia, Debrecen, Hungary
🇭🇺
Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy